Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Shipra GandhiManu R PandeyKristopher AttwoodWenyan JiAgnieszka K WitkiewiczErik S KnudsenCheryl AllenJoseph D TarioPaul K WallaceCarlos D CedenoMaria LevisSuzanne StackPauline FunchainJoseph J DrabickMark J BucsekIgor PuzanovHemn MohammadpourElizabeth A RepaskyMarc S ErnstoffPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Combination of propranolol with pembrolizumab in treatment-naïve metastatic melanoma is safe and shows very promising activity. Propranolol 30 mg twice a day was selected as RP2D in addition to pembrolizumab based on safety, tolerability, and preliminary antitumor activity.
Keyphrases
- open label
- advanced non small cell lung cancer
- clinical trial
- locally advanced
- double blind
- squamous cell carcinoma
- rectal cancer
- neoadjuvant chemotherapy
- phase ii
- phase ii study
- placebo controlled
- radiation therapy
- study protocol
- epidermal growth factor receptor
- phase iii
- randomized controlled trial
- combination therapy
- tyrosine kinase